Stock Watch: Alnylam’s Date With The Competition
Meeting Endpoints With Less Competitive Data May Not Be A Win
Executive Summary
When a loss-making rare disease biotech company’s product takes on Pfizer in the same indication but without the benefit of superior data, pharmaceutical marketing lessons will be learnt.
You may also be interested in...
Stock Watch: Filling In The Blanks In Clinical Trial Result Announcements
If a clinical trial is positive, with safety and efficacy that trounces the competition, why be coy about the details?
Alnylam Ready To Expand TTR Franchise With Positive Cardiomyopathy Results
ATTR amyloidosis patients with cardiomyopathy had statistically significant functional and quality of life improvements when treated with Onpattro (patisiran) in the Phase III APOLLO-B study.
Stock Watch: Debt And Biotech Do Not Mix
Even with higher interest rates, some debt on the balance sheets of profitable biotechs is healthy. However, among loss-making biotechs and in the current environment, raising new debt has unhealthy connotations.